Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer
Status:
Completed
Trial end date:
2017-06-12
Target enrollment:
Participant gender:
Summary
In oncology, anemia is a frequent symptom, leading to complication of patient management for,
more or less, a long term but often poorly evaluated by medical teams.
In oncology, anemia is induced by multiple causes. Iron deficiency appears to be a leading
cause of anemia, especially in people with solid cancer. Iron deficiency is characterized by
a low level of iron . Iron is a trace element required for life. It is a major component of
hemoglobin allowing the transport of oxygen in red blood cells. There are in fact 2 types of
iron deficiency: an absolute iron deficiency with a deficiency of true iron and a functional
iron deficiency. Since end of January 2014, intravenous iron-based injections have been
reclassified for cancer patients at ICO Paul Papin. The monitoring of iron deficiency with or
without anemia is currently done in our institute, the ICO-Paul Papin. There is a procedure
for the management of anemia with or without iron deficiency but there is still no
traceability of treatments performed, their compliance or even their impact on the rate
hemoglobin and the quality of life of patients during their treatment. This observatory also
makes it possible to evaluate the impact of this treatment on the quality of life of the
patients and thus allows them a personalized care of the tiredness during their treatment